317 related articles for article (PubMed ID: 28414183)
1. NKG2D: A versatile player in the immune system.
Jelenčić V; Lenartić M; Wensveen FM; Polić B
Immunol Lett; 2017 Sep; 189():48-53. PubMed ID: 28414183
[TBL] [Abstract][Full Text] [Related]
2. NKG2D stimulation of CD8
Kavazović I; Lenartić M; Jelenčić V; Jurković S; Lemmermann NAW; Jonjić S; Polić B; Wensveen FM
Eur J Immunol; 2017 Jul; 47(7):1123-1135. PubMed ID: 28378389
[TBL] [Abstract][Full Text] [Related]
3. NKG2D Promotes B1a Cell Development and Protection against Bacterial Infection.
Lenartić M; Jelenčić V; Zafirova B; Ožanič M; Marečić V; Jurković S; Sexl V; Šantić M; Wensveen FM; Polić B
J Immunol; 2017 Feb; 198(4):1531-1542. PubMed ID: 28087665
[TBL] [Abstract][Full Text] [Related]
4. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation.
Gilfillan S; Ho EL; Cella M; Yokoyama WM; Colonna M
Nat Immunol; 2002 Dec; 3(12):1150-5. PubMed ID: 12426564
[TBL] [Abstract][Full Text] [Related]
5. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
6. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells.
Karimi M; Cao TM; Baker JA; Verneris MR; Soares L; Negrin RS
J Immunol; 2005 Dec; 175(12):7819-28. PubMed ID: 16339517
[TBL] [Abstract][Full Text] [Related]
7. NKG2D induces Mcl-1 expression and mediates survival of CD8 memory T cell precursors via phosphatidylinositol 3-kinase.
Wensveen FM; Lenartic M; Jelencic V; Lemmermann NA; ten Brinke A; Jonjic S; Polic B
J Immunol; 2013 Aug; 191(3):1307-15. PubMed ID: 23804716
[TBL] [Abstract][Full Text] [Related]
8. NKG2D receptor activation of NF-κB enhances inflammatory cytokine production in murine effector CD8(+) T cells.
Whitman E; Barber A
Mol Immunol; 2015 Feb; 63(2):268-78. PubMed ID: 25089028
[TBL] [Abstract][Full Text] [Related]
9. T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines.
van Bijnen ST; Withaar M; Preijers F; van der Meer A; de Witte T; Muus P; Dolstra H
Exp Hematol; 2011 Jul; 39(7):751-62.e1-3. PubMed ID: 21554925
[TBL] [Abstract][Full Text] [Related]
10. The role of the NKG2D immunoreceptor in immune cell activation and natural killing.
Jamieson AM; Diefenbach A; McMahon CW; Xiong N; Carlyle JR; Raulet DH
Immunity; 2002 Jul; 17(1):19-29. PubMed ID: 12150888
[TBL] [Abstract][Full Text] [Related]
11. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
[TBL] [Abstract][Full Text] [Related]
12. T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.
Teng MW; Kershaw MH; Hayakawa Y; Cerutti L; Jane SM; Darcy PK; Smyth MJ
J Biol Chem; 2005 Nov; 280(46):38235-41. PubMed ID: 16169855
[TBL] [Abstract][Full Text] [Related]
13. NKG2D: A Master Regulator of Immune Cell Responsiveness.
Wensveen FM; Jelenčić V; Polić B
Front Immunol; 2018; 9():441. PubMed ID: 29568297
[TBL] [Abstract][Full Text] [Related]
14. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
15. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
Giuliani E; Vassena L; Cerboni C; Doria M
Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035
[TBL] [Abstract][Full Text] [Related]
16. NKG2D ligation without T cell receptor engagement triggers both cytotoxicity and cytokine production in dendritic epidermal T cells.
Nitahara A; Shimura H; Ito A; Tomiyama K; Ito M; Kawai K
J Invest Dermatol; 2006 May; 126(5):1052-8. PubMed ID: 16484989
[TBL] [Abstract][Full Text] [Related]
17. Immunological changes in different patient populations with chronic hepatitis C virus infection.
Szereday L; Meggyes M; Halasz M; Szekeres-Bartho J; Par A; Par G
World J Gastroenterol; 2016 May; 22(20):4848-59. PubMed ID: 27239111
[TBL] [Abstract][Full Text] [Related]
18. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.
André MC; Sigurdardottir D; Kuttruff S; Pömmerl B; Handgretinger R; Rammensee HG; Steinle A
Int J Cancer; 2012 Oct; 131(7):1601-10. PubMed ID: 21607945
[TBL] [Abstract][Full Text] [Related]
19. NKG2D and its ligands.
Obeidy P; Sharland AF
Int J Biochem Cell Biol; 2009 Dec; 41(12):2364-7. PubMed ID: 19631280
[TBL] [Abstract][Full Text] [Related]
20. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease.
Huergo-Zapico L; Acebes-Huerta A; Gonzalez-Rodriguez AP; Contesti J; Gonzalez-García E; Payer AR; Villa-Alvarez M; Fernández-Guizán A; López-Soto A; Gonzalez S
PLoS One; 2014; 9(10):e108326. PubMed ID: 25286418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]